These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Stuck in the middle. Fuyuno I Nature; 2006 Jul; 442(7100):237. PubMed ID: 16855561 [No Abstract] [Full Text] [Related]
11. Supporting the work of lesser geniuses: an argument for removing obstructions to human embryonic stem cell research. Hazuka CD Univ Miami Law Rev; 2002 Oct; 57(1):157-220. PubMed ID: 15156896 [No Abstract] [Full Text] [Related]
13. Companies balk at California's patent rules for stem cell research. Keim B Nat Med; 2007 Jan; 13(1):6. PubMed ID: 17206112 [No Abstract] [Full Text] [Related]
14. In search of the élite. Gewin V Nature; 2003 Dec; 426(6967):713-7. PubMed ID: 14668879 [No Abstract] [Full Text] [Related]
15. Good faith gone bad-gone good again. Bialy H Nat Biotechnol; 2005 Jan; 23(1):17. PubMed ID: 15637605 [No Abstract] [Full Text] [Related]
16. Take your partner by the hand.. Smaglik P Nature; 2005 Jun; 435(7046):1281. PubMed ID: 15997477 [No Abstract] [Full Text] [Related]
17. Governing stem cell research in California and the USA: towards a social infrastructure. Winickoff DE Trends Biotechnol; 2006 Sep; 24(9):390-4. PubMed ID: 16843559 [TBL] [Abstract][Full Text] [Related]
18. Good faith gone bad. Bialy H Nat Biotechnol; 2000 Nov; 18(11):1123. PubMed ID: 11062389 [No Abstract] [Full Text] [Related]
19. Tough cell to investors. Venture capitalists are wary of investing in companies in which risks in the science may not be rewarded by a health revenue stream. Moran N Sci Am; 2005 Jul; 293(1):A32-4. PubMed ID: 16008299 [No Abstract] [Full Text] [Related]
20. States race to lead stem-cell research. Scherer R Christ Sci Monitor (East Ed); 2004 Feb; ():1, 10. PubMed ID: 15457613 [No Abstract] [Full Text] [Related] [Next] [New Search]